Karyopharm Therapeutics Inc. (KPTI) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
KPTI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KPTI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 95.9% | -62.1% | -134.2% |
| 2024 | 95.9% | -82.2% | -52.6% |
| 2023 | 96.6% | -88.7% | -98.0% |
| 2022 | 96.7% | -90.5% | -105.2% |
| 2021 | 98.4% | -46.8% | -59.1% |
Download Data
Export KPTI earnings history in CSV or JSON format
Free sign-in required to download data
Karyopharm Therapeutics Inc. (KPTI) Earnings Overview
As of May 8, 2026, Karyopharm Therapeutics Inc. (KPTI) reported trailing twelve-month net income of -$125M, reflecting -90.5% year-over-year growth. The company earned $-14.38 per diluted share over the past four quarters, with a net profit margin of -134.2%.
Looking at the long-term picture, KPTI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2011.
Karyopharm Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PTCT (-$187M net income, 39.4% margin), FOLD (-$27M net income, -4.3% margin), MGNX (-$75M net income, -49.9% margin), KPTI has room to improve margins relative to the peer group. Compare KPTI vs PTCT →
KPTI Earnings vs Peers
Earnings metrics vs comparable public companies
KPTI Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$196M | -156.5% | -$91M | $-17.93 | -134.2% | -62.1% |
| 2024 | -$76M | +46.6% | -$119M | $-9.41 | -52.6% | -82.2% |
| 2023 | -$143M | +13.4% | -$130M | $-18.79 | -98.0% | -88.7% |
| 2022 | -$165M | -33.2% | -$142M | $-30.28 | -105.2% | -90.5% |
| 2021 | -$124M | +36.8% | -$98M | $-24.75 | -59.1% | -46.8% |
| 2020 | -$196M | +1.7% | -$172M | $-40.87 | -181.6% | -159.0% |
| 2019 | -$200M | -11.9% | -$189M | $-48.32 | -488.1% | -462.9% |
| 2018 | -$178M | -38.3% | -$180M | $-47.11 | -588.1% | -593.0% |
| 2017 | -$129M | -17.7% | -$131M | $-42.15 | -8036.4% | -8133.2% |
| 2016 | -$110M | +7.3% | -$111M | $-43.80 | -71153.9% | -71903.9% |
See KPTI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KPTI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KPTI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKPTI — Frequently Asked Questions
Quick answers to the most common questions about buying KPTI stock.
Is KPTI growing earnings?
KPTI EPS fell to $-14.38, with earnings declining -90.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-125M.
What are KPTI's profit margins?
Karyopharm Therapeutics Inc. net margin is -134.2%, with operating margin at -62.1%. Below-average margins reflect competitive or cost pressures.
How consistent are KPTI's earnings?
KPTI earnings data spans 2011-2025. The declining earnings trend is -90.5% YoY. Historical data enables comparison across business cycles.